The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

Methods of treating neurological inflammatory disease or seizures caused by neuroinflammation by administering cPMP are described. Treating neuroinflammatory and neurometabolic diseases with cPMP is described so as to override dyshomeostasis in the MoCo synthesis pathway and control synaptic inhibition in the gephyrin-GABAR pathway. This is a novel strategy for preventing neural circuit dyshomeostasis by stabilizing inhibitory synapses.

It is provided a method for stimulating the secretion of specialized pro-resolving mediators in a subject after the administration of a therapeutic phospholipid compositions such as CaPre®, wherein the composition also increases plasma levels of 17S-HDHA, PDX and 18RS-HEPE in the subject. Increased levels of protectins and resolvins are useful in protecting against many inflammatory-related diseases.

It is provided a method for stimulating the secretion of specialized pro-resolving mediators in a subject after the administration of a therapeutic phospholipid compositions such as CaPre®, wherein the composition also increases plasma levels of 17S-HDHA, PDX and 18RS-HEPE in the subject. Increased levels of protectins and resolvins are useful in protecting against many inflammatory-related diseases.

It is provided a method for stimulating the secretion of specialized pro-resolving mediators in a subject after the administration of a therapeutic phospholipid compositions such as CaPre®, wherein the composition also increases plasma levels of 17S-HDHA, PDX and 18RS-HEPE in the subject. Increased levels of protectins and resolvins are useful in protecting against many inflammatory-related diseases.

The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

The present disclosure relates to pharmaceutical compositions comprising PTEN inhibitors and methods of treating or preventing bone marrow loss in subjects in subjects in need thereof. The compositions and methods of this disclosure are useful in treating or preventing bone marrow loss associated with exposure to nuclear radiation or chemotherapeutic treatment.

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

Current antiretroviral therapy (ART) is a combination of 2-3 antiretroviral agents that has been successful in reducing HIV-1 RNA in the blood, and has improved the morbidity and mortality of HIV-1 infection and AIDS. Despite potent ART, eradication of HIV-1 infection remains elusive and there is potential for persistent virus replication in viral reservoirs that may continue to drive the pathogenic disease progression. Accordingly, there is a need for agents that assist in eradicating HIV-1 infection. The present invention relates to treating HIV-1 infection by administering N-carbamimidoyl-5-(1-methylpyrazol-4-yl)naphthalene-2-carboxamide in combination with antiretroviral agents.